Impact of chronic kidney disease on platelet inhibition of clopidogrel and prasugrel in Japanese patients

Background: The impact of chronic kidney disease (CKD) on the antiplatelet effect of clopidogrel and low dose (3.75 mg) prasugrel in Japanese patients is largely unknown. Methods: A total of 53 consecutive Japanese patients with stable coronary artery disease who received aspirin and clopidogrel were enrolled, and categorized by estimated glomerular filtration rate (eGFR): CKD group (n = 15, eGFR < 60 int/min/1.73 m(2)) and non-CKD group (n = 38, eGFR >= 60 ml/min/1.73 m2). Clopidogrel was switched to 3.75 mg prasugrel. Platelet reactivity measurement using the VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA) was performed at baseline (on clopidogrel) and day 14 (on prasugrel). Results: The VerifyNow P2Y12 reaction units (PRU) during clopidogrel therapy was significantly higher in the CKD group than that in the non-CKD group (185.2 +/- 51.1 PRU vs. 224.3 +/- 57.0 PRU, p = 0.02), whereas, the PRU with the prasugrel therapy in the CKD group and non-CKD group were not significantly different (149.9 +/- 51.1 PRU vs. 165.3 +/- 61.8 PRU, p = 0.36). The PRU was significantly lower with the prasugrel therapy compared to that with the clopidogrel therapy both in the CKD group and in the non-CKD group. Conclusions: Antiplatelet effect of clopidogrel but not prasugrel is attenuated in patients with CKD. Prasugrel achieves a consistently lower platelet reactivity compared with clopidogrel regardless of the presence of mild to moderate CKD. (C) 2016 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.